Aβ1−42 in CSF was widely accepted as a biomarker for AD, but histopathological evidence suggested that the Aβ1−42 level was a relatively weak predictor of severity of cognitive impairment compared with P-tau (Chandra et al., 2019). The gene discussed is MAPT; the disease is Alzheimer disease.